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Abstract 
Objectives: The COVID-19 outbreak has impacted distinct health care systems 
differently. While the rate of disease for COVID-19 is highly age-variant, there is no 
unified and age/gender-inclusive reporting taking place. This renders the comparison 
of individual countries based on their corresponding metrics, such as CFR difficult. In 
this paper, we examine cross-country differences, in terms of the age distribution of 
symptomatic cases, hospitalizations, intensive care unit (ICU) cases, and fatalities. In 
addition, we propose a new quality measure (called dissonance ratio) to facilitate 
comparison of countries’ performance in testing and reporting COVID-19 cases (i.e., 
their reporting quality).   
Methods: By combining population pyramids with estimated COVID-19 age-
dependent conditional probabilities, we bridge country-level incidence data gathered 
from different countries and attribute the variability in data to country demographics. 
Results: We show that age-adjustment can account for as much as a 22-fold difference 
in the expected number of fatalities across different countries. We provide case, 
hospitalization, ICU, and fatality breakdown estimates for a comprehensive list of 
countries. Also, a comparison is conducted between countries in terms of their 
performance in reporting COVID-19 cases and fatalities. 
Conclusions: Our research sheds light on the importance of and propose a 
methodology to use countries’ population pyramids for obtaining accurate estimates of 
the healthcare system requirements based on the experience of other, already affected, 
countries at the time of pandemics.  
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Introduction 
The first COVID-19 outbreak took place in the city of Wuhan in the Hubei province of China. 
Despite strict and robust prevention measures taken in the city, the virus has spread the rest of 
the world in a matter of a few weeks. Within three months, the World Health Organization 
(WHO) declared the outbreak a pandemic. While some more significantly than others, the virus 
has taken its toll on all countries with no exception. The global impact of COVID-19 has been 
very profound and probably unprecedented since the Spanish flu (H1N1 influenza circa 1918). 
Due to the novelty of the virus, and the nonexistence of vaccination, health professionals have 
been trying to cope with the pandemic using symptomatic treatment regimes.  
Many governments are seeking out forming different strategies that involve mitigating the spread 
until a method of prevention or a well-defined, and a successful treatment regime is found (1). 
The main focus of such mitigation effects is to alleviate the burden on healthcare systems by 
spreading out the diffusion of cases over a more extended period of time. While trying to achieve 
this, governments also face many uncertainties. One such uncertainty involves the absence of 
proven methods to accurately estimate the potential demand for healthcare services (2,3).  
At the time of this paper's writing, several governments, such as Italy and Spain, already had 
over 100% health services capacity utilization, while others were about to experience a similar 
influx of critical patients. It is clear that governments are in need of better understanding the 
dynamics of the spread for optimal or near-optimal resource allocation decisions. Unfortunately, 
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due to the emergency and the gravity of the pandemic, and the lack of scantily found hard 
evidence causes, such decisions have been made through the seat-of-the-pants approaches.  
Perhaps one of the reasons behind the lack of evidence is that there is no obvious way to map 
reports and studies pertaining to one country into another. Many regional differences make this 
mapping and transfer of the learnings and knowledge over to another domain particularly 
difficult. For the case of COVID-19, gender and age of the patient populations seem to be among 
the key drivers of such differences. Academics are acting swiftly to enrich the medical literature 
by reporting their findings on the virus-related population characteristics, diffusion patterns, 
treatment regimes, case dynamics, hospitalizations, ICU usages, and fatalities(4–7).  
In this paper, as the first objective, we build on the studies and reports that involve age-based 
clinical fatality risks (CFR), infection fatality risks (IFR), hospitalizations, ICU usages, and fatal 
outcomes. Using the latest literature as well as expert opinions, we attempt to combine data from 
different regions in order to estimate and highlight: (i) country-level differences, and (ii) 
healthcare system demands for individual age groups. Specifically, using the data from six 
different countries, we study the spread of the virus for different age groups.  
It is obvious that different countries, either due to their different policies or because of different 
healthcare infrastructures, do not perform equally well in conducting diagnostic tests and 
reporting a number of cases. Due to this fact, even countries with similar demographics and 
social distancing policies may report highly inconsistent numbers. Such inconsistencies will then 
make studying the disease’s epidemiological characteristics challenging. 
As the second objective, this paper seeks to propose an approach to compare the reporting 
performance of countries during the COVID-19 pandemic. For this purpose, we rely on the 
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countries' similarities in terms of their age pyramids as well as the stage of the disease and 
assume that similar countries should experience similar population- and age-standardized 
numbers for their infections and death tolls. Considering US as the baseline, we then calculate a 
dissonance ratio for each country as a standardized measure of their performance in reporting 
cases and mortalities (i.e., a measure of the quality of their reports). 
The rest of this paper is organized as follows: in the next section, a review of relevant studies 
from literature is provided. Following that, we describe our method and elaborate on the data 
used. The final section is dedicated to the findings and related discussions.  
Background  
The rapid spread of the novel coronavirus has even made the calculation of the rate of spread 
difficult. One frequently used way of measuring the spread is by computing the average number 
of secondary cases, or infections, that each case generates. This is known as the R-naught (𝑅0) 
(a.k.a., reproduction number) of the virus. The 𝑅0's time- and place-dependent nature (typically 
smaller in the South Asian countries, depending on social distancing interventions such as case 
isolation, partial or complete lockdowns, school closure, and distance working by the local 
authorities) is making modeling the spread of the virus a moving target (8).  
Even though the literature on COVID-19 is rapidly expanding, there is still a lack of consensus 
among academics and other scientists on the dynamics of the spread. Different estimates, for 
instance, are reported for the disease’s 𝑅0 ranging from 1.94 through 6.7 (6,9,10). This can 
perhaps be attributed to many reasons, such as the unpreparedness to a pandemic at this level, the 
lack of unified reporting systems due to diversity of health systems across the world, and the 
novelty of the pandemic itself. 
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Studies also report varying figures for other epidemiological measures such as CFR or IFR. 
Several underlying reasons may explain these variabilities. Perhaps one of the most plausible 
reasons is the abundance of undocumented cases. In their study, Li et al. (10) highlight that one 
of the reasons for the rapid spread of the virus is lack of documentation. They estimate that 
around 86% of all infections were undocumented. Another study from South Korea suggests 
similar undocumented case percentages at around 55-86% (11). News also suggests that even 
mortality cases often go unreported. A recent article in The Economist (12) highlighted stark 
differences between the number of expected death cases (including those attributed to COVID-
19) and the actual death cases. Their estimation, based on regions’ normal death rates, suggests 
the actual death-toll of the novel COVID-19 being more than double of what is being reported in 
different regions in Italy, Spain, and France. Perhaps this may be one of the reasons for 
conflicting CFR and IFR figures reported in the literature. While some studies suggested an 
estimated case fatality risk of as high as 7.2% (13) in Italy, other studies reported a CFR of 3.4% 
in China (14), and 2.3% using the age-adjusted Diamond Princess cruise ship data (15). More 
recent works report somewhat lower case fatality rates circa 1.4-1.5%% (16,17), both using data 
from Wuhan.  
Similar variations also hold for IFR. Studies report IFRs as low as 0.5% using the Diamond 
Princess cruise ship data (15), 0.94%, and 0.657% using Wuhan data (18) and (19), respectively. 
Even though these numbers significantly differ from each other, there seems to be (i) 
convergence to a CFR of 1.5% over time, (ii) CFR/IFR ratio appears to hover around 2-3, 
indicating as much as 40-70% asymptomatic cases of the virus.   
One of the apparent reasons behind the differences in reported CFRs and IFRs is the different 
demographics in different countries. As the virus affects the elderly more than the young, the 
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virus takes a different toll on each country, depending on its age demographics (15,20). There 
may be several other reasons, including the fact that the age distribution of the infected 
population may differ from the overall age distribution. Hence, 𝑅0 may significantly differ across 
age groups. However, there is a lack of by-age (and gender)-group reporting. For instance, Raj 
Bhopal (21), in his article expresses the importance and urgency of adjusting/reporting age and 
gender breakdowns of COVID-19 related data. 
In this paper we pursue two objectives; First, we take into account the cross-country age 
disparities to handle such inconsistencies by providing country-independent conditional 
probabilities for each age group and then estimating the number of infections, hospitalizations, 
ICU visits, and mortality for each country given its age distribution. To this end, we assume that 
deaths, hospitalizations, and ICU usages are proxy measures for COVID-19 spread, also that 
similar spread patterns apply to each age group across countries—the virus is identical across all 
countries. We also demonstrate some evidence for the acceptability of these assumptions.  
Second, relying on our findings from the first part, we propose a measure to assess the quality of 
testing and reporting COVID-19 cases across countries and comparing countries’ performance in 
those manners. We believe that lack of such a measure in the literature has led to many studies 
relying on poor quality COVID-19 data in their analyses, which may lead to misleading 
conclusions. 
Method and Dataset 
Many of the existing studies that are focused on modeling the spread of the COVID-19 have 
been using a few different models such as susceptible-infected-recovered (SIR) and its covariates 
(mainly SEIR: susceptible-exposed-infected-recovered, or Sidarthe model) (22–26). These 
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studies often ignore age-dependent variations from one country to another, or are limited to one 
country, or sometimes two (1). 
In this study, instead of computing the spread of the virus, we look at the results of different 
scenarios. Specifically, we design three different spread scenarios (mild, moderate, and severe) 
by transferring knowledge learned from the seasonal flu pandemic as well as existing estimates 
for COVID-19 spread measures (R0, proportion of symptomatic infections (C), and proportion of 
reported cases) from the literature. Then taking into account expert opinions, we choose the best 
scenario (closest one to their opinions).  
The best scenario is then used, along with the US (our baseline country) population age 
distribution, to calculate a set of conditional probabilities to estimate probability of infection, 
hospitalization, ICU admission, and death for a given person from each age group. At the end, 
the calculated probabilities are applied to the countries’ age pyramids to estimate cases, 
hospitalizations, ICU usage, and fatalities in each country (adjusted for their population age 
distribution). 
Scenarios and Expert opinions 
While aggressive quarantines and enforcing/recommending social distancing can change the 
outcome of the burden on healthcare systems, the primary health care capacities are the 
bottleneck for almost all countries. The size of the susceptible population typically depends on 
different 𝑅0 values. By enforcing/recommending social distancing, governments attempt to 
mitigate the situation and reduce this number (Figure 1).  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted September 2, 2020. .https://doi.org/10.1101/2020.08.31.20185223doi: medRxiv preprint 
9 
 
 
Figure 1. Different 𝑅0 values and corresponding estimated percent of susceptible populations.  
The novel coronavirus is often compared and contrasted against seasonal flu. Using CDC 
numbers over the last two flu seasons (2017-2019), we estimate the following table for the 
seasonal flu for comparison purposes. 
Table 1. The seasonal flu numbers from the CDC. 
Seasonal flu (based on CDC data) US Cases 
As % of Susceptible 
Population 
Per 1M 
Susceptible population (R0=1.3) 134.4M 100.00% 420,000 
Population with symptoms 40M 29.80% 121K 
Medical Visits 15M 11.10% 45.5K 
Hospitalization 0.6M 0.44% 1,823 
Fatality 40K 0.03% 121 
CFR 0.03%   
 
We construct an analogous table to seasonal flu using expert opinions (27,28) (See Table 2). To 
this end, we constructed different scenarios severe (Scenario 1) to mild (Scenario 3) based on the 
estimates provided by the existing literature. We construct this table for the United States. By 
making use of suggested estimates based on (27,29), we create a range of possible 𝑅0 values 
R0=1.3, 42.00%
R0=2.2, 84%
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(i.e., 1.5-2.2) to estimate the percentage of susceptible population. Using the literature, we then 
estimate upper and lower limits for symptomatic cases, reported cases (not all of the 
symptomatic cases are reported), hospitalizations (as a percentage of reported cases), as well as 
ICU cases (in terms of cases), and fatalities in an age-adjusted manner.  
Estimating fatalities is challenging since case fatality rates depend on a number of factors, 
including:  
(i) The number of tests (and therefore, the number of positive cases) conducted each 
individual country. Many countries—excluding countries such as Iceland, where a 
significant portion of the population was tested—conduct selective testing. This 
may involve a selection bias where only the people with severe enough symptoms 
may be tested.  
(ii) The delay between the symptom onsets and the time of deaths.  
(iii) The varying levels of adequacy/inadequacy of the healthcare systems.  
(iv) The rates of smoking or the prevalence of chronical illnesses. We chose to use 
CFR of 1.5% for the United States for our analysis.  
  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted September 2, 2020. .https://doi.org/10.1101/2020.08.31.20185223doi: medRxiv preprint 
11 
 
Table 2. Different COVID-19 spread estimates for the United States (numbers are in millions) 
COVID-19 Scen. 1 Scen. 2 Scen. 3 
Expert 
Opinion 1 
Expert 
Opinion 2 
Susceptible population (overall R0={2.21, 1.8, 1.52}) 276.4 240.2 190.8 160-210M - 
The population with symptoms {.503, .35, .204}(C) 138 84 38 - - 
Reported cases (as the ratio of symptomatic cases) {.115, .15, .206} 27.6 13 4.2 - - 
Hospitalizations (36%7,8 of reported cases)(H) 10 4.5 1.5 2.4-21M - 
ICU patients (% of Hospitalizations–7.4%9,10)(I) 0.7 0.34 0.11 - ~0.0811 
Fatalities (D) 0.41 0.19 0.063 0.2-1.7M 0.03-0.12 
CFR {1.512,13} 1.50% 1.50% 1.50% 
 
 
1 (10)Error! Bookmark not defined. : estimates 𝑅0 value as 2.2 for Wuhan data.  
2 (30) estimates 𝑅0 value as 1.5 for South Korea where the virus is relatively better contained  
3 (17) finds a 50% chance of developing symptoms using Wuhan data.  
4 (31) suggests that the ratio of asymptomatic cases could be as high as 80%.  
5 (32) uses South Korean data and similar age corrections and estimate that only around 11% of cases are reported in the US. 
6 (33) uses an estimation interval of 40-60% in their analysis. However, we construct our scenarios using similar to the US-based study. 
7 (34) CDC estimates also yield a similar number in the US. However, the data has no age breakdown and includes some unknown cases. 
8 The rate is estimated as 0.36 using conditional probabilities and age distributions based on Spanish Data (35)  
9 (29) estimates that around a fifth of hospitalization days will require ICU stays for the US. However, they do not provide projections based on 
the number of hospitalization and ICU cases. Their numbers are in seem consistent with Spanish data (35).  
10 The crude rate is estimated as 7.4% of total hospitalizations using Spanish Data (35)Error! Bookmark not defined. . However, each case stays 
in ICU for an average of 15 days (36). (0.074 x 15 = 1.11) 
11 Assuming a 10-day average duration of stay.  
12(16,17) indicated a CFR of 1.5%.  
13 (37) indicates 0.7% CFR in Germany; such numbers usually come from countries where the spread is better contained.   
 
Based on the characteristics of the COVID-19, the Center for Disease Control (CDC) estimated 
that 2.4 to 21 million Americans would require hospitalization, and a death-toll of as much as 
480,000 may be expected (27). According to the same projection, the death toll could be any 
figure from 200,000 to as high as 1.7 million. Another more recent estimate assuming full social 
distancing through May (as of April 8, 2020), the White House estimated this figure to fall 
between 30,000 and 126,000 (28). These numbers are shown in the last two columns of Table 2. 
Given the closeness of estimates made by Scenario 3 (the mildest scenario) and the expert 
opinions, we rely on that scenario for establishing the conditional probabilities discussed in the 
following section. 
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Conditional Probabilities 
In this study, we use countries’ age distributions (population pyramids) and data involving 
different countries to create country-independent conditional probabilities for each age group. 
The severity of COVID-19 is also gender-dependent. However, due to the unavailability of data, 
we did not take gender into account.  
As discussed earlier, we report our findings using the mildest of the three scenarios since its 
estimates turned out to be more consistent with the expert opinions (see Table 2). We use the 
following notation to formulate the conditional probabilities for each age group:  
E: Events, E = {C: Case, A: Age, H: Hospitalization, I: Intensive Unit Care, D: Death) 
𝑃(𝐶): The probability of being infected with symptoms. Using the scenario-2 with 
𝑅0=1.8, we estimate the proportion of the susceptible population as 0.73, with a 35% 
probability of developing symptoms: 𝑃(𝐶) = 0.35 × 0.73 
𝑃(𝑅): The probability of being a reported case: 𝑃(𝑅) = 𝑃(𝐶) × .15 
𝑃(𝐻): The probability of hospitalization. This number depends on the percentage of 
reported cases, as well as the size of the population with symptoms. Using 0.15 and 36% 
of the rate of hospitalization we use (𝑃(𝐻) = 𝑃(𝐶) × .11 × .36)  
𝑃(𝐼): The probability of needing ICU (𝑃(𝐼) = 𝑃(𝐻) × 0.074) 
𝑃(𝐷): The probability of death for the cases (CFR) (𝑃(𝐷) = 𝑃(𝑅) × .015) 
𝑃(𝐴𝑖): The probability of each age group i for a given country (using the country 
population pyramid) 
𝑃(𝐶|𝐴𝑖): The probability of being infected with symptoms given age group i  
𝑃(𝐶|𝐴𝑖) =
𝑃(𝐴𝑖|𝐶)
𝑃(𝐴𝑖)
𝑃(𝐶)  
where 𝑃(𝐴𝑖|𝐶): The probability of the age group i, given case.  
We compute other conditional probabilities similarly for events {H, I, D} and then use them to 
simulate the mild scenario breakdowns for the United States. By using population pyramids and 
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the US data, we replicate the same scenario for each individual country and report the results 
(per 1 million residents). 
Assessment of Quality of COVID-19 Case Reporting 
The second question this study seeks to address is that during the COVID-19 pandemic, how 
well different affected countries performed in conducting tests and reporting the cases. In order 
to answer this question, it is critical to have a base for comparing the countries' performance with 
one another (i.e., to assess their relative quality of reporting). For this purpose, through a series 
of calculations described below, we estimate an age-standardized expected number of cases and 
fatalities for each country, such that countries can be compared regardless of their age 
distributions. The procedure is explained below. 
Using conditional probabilities, we calculate a set of successive measure for each country 
described below:  
a. Age-Adjustment Fatality Coefficient (AAFC): We calculate the age-adjusted expected 
number of deaths by setting the global fatality baseline coefficient at "1" for the world. 
The coefficient value higher than “1” typically corresponds to an aging population. For 
instance, we estimate AAFC for Japan (one of the oldest nations in the world) as 3.41 
(1037/204 from Table 1) and AAFC for Niger (the youngest nation) as 0.15. A 22-fold 
difference.  
b. Age-Adjusted ICU Coefficient (AAICUC): The number of expected ICU cases 
corresponding to corresponding to AAFC of one.  Calculated using the formula: 
 
𝐴𝐴𝐼𝐶𝑈𝐶 =
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐼𝐶𝑈 𝑐𝑎𝑠𝑒𝑠
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐹𝑎𝑡𝑎𝑙𝑖𝑡𝑖𝑒𝑠
× 𝐴𝐴𝐹𝐶 
 
Countries with AAICUC of greater than the global average, 2.26, typically are expected 
to have heavier demand per capita for their intensive care units.  
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c. Age-Adjusted Hospitalization Coefficient (AAHC): The number of expected 
hospitalization cases corresponding to AAFC of one. Calculated using the formula: 
 
AAHC= 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛𝑠 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐹𝑎𝑡𝑎𝑙𝑖𝑡𝑖𝑒𝑠
× 𝐴𝐴𝐹𝐶 
 
d. Cumulative Fatalities (CF): Number of cumulative fatalities for each country as of May 
13.   
e. Day-Adjusted Cumulative Cases (DACC): Using a sliding lag window, we estimated the 
average number of days from the case reported to recovery (or fatality) as 8 days (38). 
Therefore, DACC corresponds to the reported cumulative number of cases 8 days prior to 
CF numbers.  
f. Actual Case Fatality Risk (ACFR): Calculated as CF/DACC 
g. Expected Infections per Fatality (EIPF): A recent study estimated the IFR of COVID-19 
to be 1.3 for the US (39). Using this value for the US by adjusting AAFC of the US 
yields:  
𝐸𝐼𝑃𝐹𝑈𝑆 =
1.89
0.013
= 145 
 
The figure represents the number of infections in the US, corresponding to one fatality at 
the baseline. Values for other countries are calculated using 
𝐸𝐼𝑃𝐹𝑖 =
𝑅𝐼𝑃𝐹𝑖
𝑅𝐼𝑃𝐹𝑈𝑆
× 𝐸𝐼𝑃𝐹𝑈𝑆 
Countries with higher numbers are expected to report more cases than that of the US.  
h. Reported Infections per Fatality (RIPF): Calculated as 1/ACFR for each country.  
i. Age-adjusted Reported Fatalities per 1M (AARFPM): Some countries, given their 
population pyramids, are expected to report more cases. This column age and population 
(per 1M) adjusts the CF values for each country. Note that AARFPM values depend on 
the stage of the spread.  
j. Dissonance Ratio (DR): Calculated as RIPF/ACFR. A value (typically less than 1) that 
indicates how well two or more countries with roughly the same AARFPM values 
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performed in testing and reporting COVID-19 cases. Smaller DR values indicate possible 
under-reporting by the corresponding country.  
 
Results 
Age-adjusted Estimates of COVID-19 
Unfortunately, the only source of data that explicitly provided the age breakdowns of 
hospitalization and ICU cases (P(A|H), and P(A|I)) we could found was Spain (35). After 
comparing the estimated P(H) and P(I)s from Spain data and the data from the Institute for 
Health Metrics and Evaluation (28), we concluded the numbers are consistent and decided to use 
age breakdowns from the Spanish dataset as the baseline for calculating conditional probabilities. 
A sample table, including some of the probabilities using the reports by the Spanish Ministry of 
Health, is given in Table 3.  
Table 3. Probabilities and conditional probabilities for Spain 
Age Group P(A) 
#Inf. 
Cases 
P(A|C)  
#Hosp. P(A|H) 
#ICU 
cases P(A|I) #Deaths P(A|D) 
0-9 9.3% 130 0.6% 35 0.45% 1 0% 0 0.0% 
10-19 10.0% 226 1.1% 20 0.26% 1 0% 1 0.1% 
20-29 10.0% 1,352 6.6% 200 2.6% 10 2% 4 0.5% 
30-39 13.2% 2,386 11.7% 431 5.6% 18 3% 3 0.4% 
40-49 17.0% 3,190 15.6% 778 10.1% 45 8% 9 1.1% 
50-59 14.9% 3,433 16.8% 1,074 13.9% 106 18% 20 2.5% 
60-69 11.1% 3,179 15.6% 1,432 18.6% 162 28% 63 7.8% 
70-79 8.4% 3,304 16.1% 1,858 24.1% 192 34% 164 20.4% 
80+ 6.2% 3,271 16.0% 1,871 24.3% 38 7% 541 67.2% 
 
Using age-corrections via conditional probabilities also shows that reported numbers are quite 
consistent across-countries (Table 4). As shown in this table, there is a 0.97 correlation between 
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the estimated and the reported age group probabilities for the United States, suggesting the 
acceptable performance of the proposed approach for age adjustments. 
Table 4- Computing age group probabilities for given cases in (i) Spain, (ii) in the US calculated using Spain data, 
and (iii) reported by CDC. While the correlation between (i) and (iii) is .88, the correlation between (i) and (ii) is as 
high as .97.  
Age Group 𝑃(𝐴)𝑈𝑆 𝑃(𝐴)𝑆𝑝 𝑃(𝐴|𝐶)𝑆𝑝 
𝑃(𝐴|𝐶)𝑈𝑆 from 
Spain data 
𝑃(𝐴|𝐶)𝑈𝑆 
reported 
0-9 12.1% 9.3% 0.6% 0.9% 2.5% 
10-19 12.9% 10.0% 1.1% 1.6% 2.5% 
20-29 14.0% 10.0% 6.6% 10.5% 11.5% 
30-39 13.4% 13.2% 11.7% 13.3% 11.5% 
40-49 12.2% 17.0% 15.6% 12.7% 14.5% 
50-59 12.9% 14.9% 16.8% 16.4% 17.5% 
60-69 11.5% 11.1% 15.5% 18.1% 17.1% 
70-79 7.0% 8.4% 16.1% 15.1% 12.6% 
80+ 3.9% 6.2% 16.0% 11.4% 10.2% 
 
We then use country demographics, CDC estimations for the US, and data sets available (shown 
in Table 5) to compute age-adjusted probabilities and number of cases for each of the events 
(Susceptible, Case with symptoms, Hospitalization, IUC case, and Deaths). For all countries, we 
report all numbers per 1 million for easy comparison in Appendix Table 1Appendix Table 2.  
Table 5- Datasets used in this study 
Country 
South 
Korea(30) Spain(35) US(30) China(19) Italy(13) 
Number of cases 6,284 20,471 2,449 44,669 ~34,000 
Number of hospitalizations - 7,699 - - - 
Number of ICU cases - 573 - - - 
Number of fatalities in the study 42 805 44 805 1,625 
 
Studies report different case- and death-related age-breakdowns for a variety of countries. We 
observed that taking conditional probabilities—based on population age distributions in 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted September 2, 2020. .https://doi.org/10.1101/2020.08.31.20185223doi: medRxiv preprint 
17 
 
individual countries—into account, we can help mitigate the variability in the reported results. 
Figure 2 visually confirms the reduction in inconsistencies by taking age adjustments into 
account.  
 
Figure 2. Age breakdown patterns of cases with (left) and without (right) taking country population 
pyramids (in terms of conditional probabilities) into account.  
Figure 3 also highlights the age distribution differences for different events. ICU beds and 
invasive ventilators are in short supply, and some health systems prioritize younger patients over 
the older ones in order to increase the chances of survival. While debated from ethical 
viewpoints, the figure also demonstrates such preferences.    
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Figure 3. Age pyramids for cases, hospitalization, ICU uses, and fatalities for Spain. 
Assessing Countries’ Reporting Quality 
As explained earlier, for each country, we calculated a dissonance ratio (DR) number indicating 
how well the governments have done in conducting tests and reporting cases, given some age-
standardized expected number of cases. The DR estimates (along with other related measures) 
are reported in detail in Appendix Table 2.  
At the time of writing this manuscript, some of the countries were still experiencing the early 
stages of the breakout. At the end of the COVID-19 spread, the Appendix Table 2 would include 
similar values in column AARFPM across all countries. As AARFPM values indicate the 
progress for the breakout, we filtered out the countries with less than 10 AARFPM for better 
interpretability. This column, therefore, may be interpreted as a crude measure of reliability 
(hence progress of the spread) for dissonance ratios (i.e., the higher this value, the more evidence 
we have for the magnitude of the dissonance). Therefore, the table is ordered by AARFPM 
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values rather than dissonance ratios. The correct way of interpreting the results is by comparing 
the DR values of row-wise nearby countries (with similar AARFPM values). For instance, 
Finland, Hungary, and Israel have similar AARFPM values (20.1, 20.2, and 20.6, respectively) 
indicating them being at the same stage of the epidemic. However, their Dissonance Ratios are 
0.04, 0.23, and 0.55, respectively. This indicates comparatively better case reporting (including 
testing) by Israel. At the end of the pandemic, all countries in the table are expected to have 
roughly the same AARFPM values, making reporting quality of them all comparable to one 
another through the proposed standardized DR measure. 
Discussion 
In this paper, we focus on age-dependent breakdowns of cases, hospitalizations, ICU usages, and 
fatalities (events) using a range of scenarios. We construct these scenarios by using expert views 
and existing reports in the literature and based on the US data. We then use conditional 
probabilities to compute age-standardized breakdowns for the events for all individual countries.  
Our results propose a few important implications. First, the results highlight the effect of 
demographical differences across countries on COVID-19 spread. Figure 4 indicates a 
comparison between Niger and Japan (as the youngest and oldest populations in the world, 
respectively). It suggests, provided that everything else remains the same, the death toll 
difference due to age demographics could be as much as 20 times (47 vs. 1,037 deaths per 1M 
population according to Appendix Table 1).  
Second, our results have the potential to help decision-makers to accommodate age-specific 
aspects of the spread. Creating different age-based isolation strategies, depending on the age-
demographics of individual countries, may be considered. This is essentially important given the 
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limited capacity of health care systems in the affected countries. At this time, one of the major 
concerns of the governments in the countries affected by COVID-19 is to have reliable estimates 
of medical requirements to plan ahead proper measures. We argue that providing such estimates 
based on age groups can give the authorities a clearer picture of what they should expect in 
different regions of their countries based on the demographic profile of the population in each 
region. The proposed approach is not exclusively for COVID-19 and may be employed by the 
decision-makers for estimating capacity requirements in the future epidemic situations. 
Also, our study attempts to combine several parameters calculated or taken from different 
academic papers, reports, or data sources together in creating a range of scenarios. While this 
approach provides a somewhat holistic view of the phenomenon, it also omits other country-level 
differences such as social isolation policies, prevention strategies, and the effectiveness of the 
individual healthcare systems (i.e., our research limitations). Future research may extend the 
proposed approach by involving such factors (upon the availability of data for them) in the 
calculation of conditional probabilities. Appendix Table 1 must be interpreted as a comparison 
tool for different countries’ exposure to the virus.  
Additionally, we propose an approach to compare countries’ performance in reporting COVID-
19 cases. Clearly, not all countries have the same healthcare infrastructure to conduct enough 
number of tests to identify infected people. Despite these differences, official reports published 
by the governments of different countries are being used in a similar manner to study the 
characteristics of the novel coronavirus, which may cause significant bias to their findings. It is 
crucial then to provide a means to recognize those countries that perform better in running tests 
and reporting cases, thereby providing more reliable numbers for studying the pandemic. 
Appendix Table 2 lays out a base for comparing the reporting performance of the countries by 
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taking into account their age disparities as well as the progress stage of the disease. Using that 
tool, researchers could have a better understanding of the accuracy of reported numbers by each 
country by looking into their dissonance ratio number. 
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Figure 4. Age-dependent event estimations for the US, the country with the youngest population in the world (Niger), and with the oldest (Japan). y-axis is for 
scaling purposes based on one of the scenarios per 1M.  
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Appendix 
Appendix Table 1- Scenario-2 based event breakdowns for individual countries 
Country 
Population 
(K) 
Cases per 
1M Hosp. per 1M 
ICU per 
1M Deaths per 1M 
Portugal 10,196 275,770 16,717 1,218 854 
Germany 83,783 275,671 16,521 1,194 852 
Italy 60,461 275,463 16,903 1,223 902 
Greece 10,423 273,517 16,472 1,173 879 
Switzerland 8,655 272,148 15,554 1,130 720 
Bulgaria 6,949 271,055 16,053 1,216 706 
Japan 126,475 271,042 17,430 1,256 1,037 
Hungary 9,660 270,439 15,464 1,160 665 
Finland 5,542 270,389 16,135 1,195 784 
Netherlands 17,136 269,922 15,626 1,169 705 
Spain 46,733 269,495 15,673 1,117 772 
Republic of Korea 51,270 269,133 14,500 1,102 556 
Romania 19,236 268,786 15,330 1,133 677 
Poland 37,847 267,820 15,109 1,113 656 
Belgium 11,589 267,496 15,314 1,104 736 
Denmark 5,792 266,784 15,340 1,144 694 
Czech 10,708 265,466 15,251 1,153 642 
Sweden 10,099 264,504 15,248 1,108 729 
United Kingdom 67,886 264,035 14,909 1,078 694 
Ukraine 43,734 263,634 14,445 1,065 598 
Norway 5,421 261,559 14,405 1,060 619 
Cuba 11,326 260,576 13,965 1,038 562 
Belarus 9,449 256,685 13,641 1,004 548 
US 329,064 255,500 13,797 1,021 575 
New Zealand 4,822 254,069 13,778 1,022 576 
Australia 25,498 253,440 13,696 993 590 
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Country 
Population 
(K) 
Cases per 
1M Hosp. per 1M 
ICU per 
1M Deaths per 1M 
Russian Federation 145,935 253,217 13,567 997 551 
Uruguay 3,474 244,333 12,945 912 586 
Ireland 4,938 242,002 12,670 941 493 
Chile 19,116 234,534 11,579 853 429 
China 1,439,324 227,809 10,805 875 326 
Argentina 45,197 213,004 10,468 759 400 
Israel 8,655 211,875 10,745 771 438 
Sri Lanka 21,413 211,258 10,060 822 304 
Brazil 212,560 207,735 9,592 722 318 
Colombia 50,883 198,163 9,060 679 301 
World 7,794,799 197,313 9,131 688 304 
Tunisia 11,819 196,661 8,884 680 281 
Turkey 84,339 195,387 8,928 677 290 
Peru 32,972 191,468 8,717 649 290 
Viet Nam 97,338 190,509 8,391 608 284 
Kazakhstan 18,776 181,352 8,042 604 258 
Venezuela (Bolivarian 
Republic of) 
28,437 180,853 8,072 628 247 
Mexico 128,933 177,978 7,887 589 256 
Dominica 10,847 174,998 7,815 574 263 
Azerbaijan 10,139 173,391 7,261 557 214 
Ecuador 17,643 173,165 7,726 571 257 
Morocco 36,910 172,690 7,503 604 214 
Malaysia 32,365 168,392 7,211 575 205 
Bolivia 11,674 163,184 7,436 533 267 
Iran (Islamic Republic 
of) 
83,993 161,603 6,787 541 189 
Algeria 43,852 159,997 6,934 521 217 
Paraguay 7,132 155,116 6,797 516 213 
India 1,380,004 154,638 6,475 529 176 
Indonesia 273,523 154,124 6,343 531 165 
Bangladesh 164,690 142,614 5,915 448 177 
Philippines 109,581 136,985 5,625 457 152 
Nepal 29,138 133,698 5,539 465 145 
South Africa 59,308 132,704 5,360 455 135 
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Country 
Population 
(K) 
Cases per 
1M Hosp. per 1M 
ICU per 
1M Deaths per 1M 
Turkmenistan 6,031 129,106 5,120 398 143 
Egypt 102,335 129,065 5,306 440 140 
Uzbekistan 33,470 128,528 5,038 401 135 
Syrian Arab Republic 17,500 125,473 5,083 400 141 
Pakistan 220,892 112,174 4,521 370 119 
Jordan 10,205 108,890 4,301 345 114 
Saudi Arabia 34,815 102,129 3,777 317 91 
Sudan 43,849 93,224 3,681 308 93 
Ethiopia 114,964 88,752 3,545 291 93 
Iraq 40,223 88,523 3,410 280 87 
Iraq 40,223 88,523 3,410 280 87 
South Sudan 11,195 85,682 3,366 285 84 
State of Palestine 5,101 85,658 3,307 278 82 
Madagascar 27,692 82,226 3,138 265 77 
Ghana 31,073 79,587 2,934 280 63 
Senegal 16,745 77,735 2,989 261 71 
Democratic Republic of 
the Congo 
89,561 76,412 2,970 255 72 
Yemen 29,825 74,766 2,840 250 67 
Mozambique 31,255 71,548 2,752 239 66 
Somalia 15,893 70,564 2,714 242 63 
Côte d'Ivoire 26,378 68,960 2,558 243 55 
Cameroon 26,545 68,088 2,540 232 57 
United Republic of 
Tanzania 
59,734 66,731 2,484 229 55 
Afghanistan 38,928 66,159 2,469 227 55 
Kenya 53,771 66,064 2,407 219 53 
Nigeria 206,139 60,712 2,193 228 43 
Burkina Faso 20,903 60,006 2,200 209 47 
Mali 20,249 59,879 2,230 207 49 
Niger 24,207 59,262 2,215 215 47 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted September 2, 2020. .https://doi.org/10.1101/2020.08.31.20185223doi: medRxiv preprint 
29 
 
Appendix Table 2- Measuring the gap between expected case reporting vs. actual case reporting 
Country Popul. (K) ACFR RIPF EIPF DR AARFPM CF DACC AAHC AAICUC AAFC 
Belgium 11,589 17.4% 5.73 161 0.04 310.3 8,707 49,906 50.4 3.63 2.42 
United Kingdom 67,886 17.2% 5.82 157 0.04 206.9 32,065 186,599 49.0 3.55 2.28 
Italy 60,461 14.6% 6.86 178 0.04 171.3 30,739 210,717 55.6 4.02 2.97 
Sweden 10,099 14.6% 6.85 161 0.04 134.4 3,256 22,317 50.2 3.64 2.40 
Hungary 9,660 14.0% 7.14 163 0.04 20.1 425 3,035 50.9 3.82 2.19 
Netherlands 17,136 13.4% 7.44 165 0.05 137.2 5,456 40,571 51.4 3.85 2.32 
Spain 46,733 12.3% 8.13 165 0.05 225.3 26,744 217,466 51.6 3.67 2.54 
Mexico 128,933 15.2% 6.57 85 0.08 32.9 3,573 23,471 25.9 1.94 0.84 
Romania 19,236 7.4% 13.54 162 0.08 22.6 972 13,163 50.4 3.73 2.23 
Brazil 212,560 11.4% 8.78 101 0.09 51.8 11,519 101,147 31.6 2.38 1.05 
US 329,064 7.0% 14.35 145 0.10 129.6 80,684 1,158,041 45.4 3.36 1.89 
Ireland 4,938 6.8% 14.66 134 0.11 183.1 1,467 21,506 41.7 3.10 1.62 
Denmark 5,792 5.6% 17.87 162 0.11 40.3 533 9,523 50.5 3.76 2.28 
Finland 5,542 5.2% 19.39 170 0.11 18.9 271 5,254 53.1 3.93 2.58 
Switzerland 8,655 5.2% 19.34 164 0.12 75.2 1,542 29,822 51.2 3.72 2.37 
Algeria 43,852 11.3% 8.82 72 0.12 16.2 507 4,474 22.8 1.71 0.71 
Germany 83,783 4.6% 21.66 174 0.12 32.0 7,533 163,175 54.3 3.93 2.80 
World 7,794,799 8.2% 12.13 96 0.13 36.6 285,760 3,465,608 30.0 2.26 1.00 
Portugal 10,196 4.5% 22.31 176 0.13 39.9 1,144 25,524 55.0 4.01 2.81 
Czech 10,708 3.6% 27.59 161 0.17 12.4 282 7,781 50.2 3.79 2.11 
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Country Popul. (K) ACFR RIPF EIPF DR AARFPM CF DACC AAHC AAICUC AAFC 
Bolivia 11,674 7.7% 13.07 76 0.17 11.9 122 1,594 24.5 1.75 0.88 
Ecuador 17,643 7.3% 13.77 77 0.18 143.8 2,145 29,538 25.4 1.88 0.85 
Iran 83,993 6.9% 14.57 78 0.19 128.0 6,685 97,424 22.3 1.78 0.62 
Philippines 109,581 7.9% 12.70 62 0.20 13.2 726 9,223 18.5 1.50 0.50 
Egypt 102,335 8.2% 12.13 54 0.22 11.3 533 6,465 17.5 1.45 0.46 
Norway 5,421 2.9% 34.86 152 0.23 20.2 224 7,809 47.4 3.49 2.04 
Dominican Republic 10,847 4.9% 20.24 83 0.24 41.8 393 7,954 25.7 1.89 0.87 
Peru 32,972 4.3% 23.42 94 0.25 62.3 1,961 45,928 28.7 2.13 0.95 
Turkey 84,339 3.0% 32.82 94 0.35 47.7 3,841 126,045 29.4 2.23 0.95 
Somalia 15,893 7.2% 13.88 29 0.48 15.7 52 722 8.9 0.80 0.21 
Chile 19,116 1.6% 60.88 122 0.50 11.9 323 19,663 38.1 2.81 1.41 
Israel 8,655 1.6% 62.82 113 0.55 20.6 258 16,208 35.3 2.54 1.44 
Burkina Faso 20,903 7.6% 13.24 23 0.57 15.4 50 662 7.2 0.69 0.15 
Cameroon 26,545 6.0% 16.62 27 0.62 25.1 125 2,077 8.4 0.76 0.19 
Mali 20,249 6.9% 14.44 23 0.62 11.9 39 563 7.3 0.68 0.16 
Niger 24,207 6.1% 16.30 24 0.69 12.2 46 750 7.3 0.71 0.15 
Afghanistan 38,928 4.5% 22.16 26 0.85 17.3 122 2,704 8.1 0.75 0.18 
Saudi Arabia 34,815 0.9% 105.93 45 2.34 24.4 255 27,011 12.4 1.04 0.30 
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